Drug intelligence / Profile preview

KMA Bispecific

Development stage: Unknown
Lead developer: HaemaLogiX
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

KMA Bispecific is a bispecific monoclonal antibody developed by HaemaLogiX. It functions as an inhibitor of kappa myeloma antigen (KMA), also known as kappa myeloma antigen inhibitors. The drug is designed to target the KMA protein, which is associated with multiple myeloma and potentially other neoplasms, immune system diseases, and cardiovascular diseases. As a bispecific antibody, it can simultaneously bind two different antigens or epitopes, enhancing its therapeutic potential in cancer immunotherapy by recruiting immune cells or interfering with disease-related signaling pathways[1][7]. Its primary indication under investigation is multiple myeloma[1].

Targets

Immunoglobulin light chainCD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on KMA Bispecific.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KMA Bispecific.

Explore the full profile